title: A randomized trial of a fixed high dose vs a weight-adjusted low dose of intravenous heparin during coronary angioplasty.
abstract: OBJECTIVE
  Prospectively to compare success rate and complications in percutaneous transluminal coronary angioplasty using two doses of heparin.
  
  
  RESULTS
  Four hundred patients undergoing coronary angioplasty were randomly assigned to receive 15,000 IU (group A) or 100 IU.kg-1 (group B) of heparin. The angioplasty success rate was 95% of both groups. Stents were placed in 28.5% and 26.5% of patients in groups A and B, respectively (P = 0.73). The primary endopoint (freedom from death, myocardial infarction, unplanned revascularization or bailout stenting) occurred in 91% vs 95% of patients in groups A and B, respectively (odds ratio: 1.88, 95% CI: 0.80-4.50, P = 0.12). Haemoglobin loss was 0.36 +/- 1 and 0.27 +/- 0.9 g.dl-1 in groups A and B, respectively (P = 0.37). The time to sheath removal (735 +/- 265 vs 558 +/- 246 min) and the time to transfer to a stepdown unit (12.7 +/- 4.5 vs 9.8 +/- 4.2 h) were longer in groups A (P = 0.0001 for both comparisons).
  
  
  CONCLUSIONS
  A weight-adjusted low dose of intravenous heparin is at least as safe as a fixed high dose for coronary angioplasty. It allows earlier sheath removal and discharge to a stepdown unit.
authors.affiliation: Service de Cardiologie, Höpital Bichat, Paris, France.
authors.forename: A
authors.initials: A
authors.lastname: Boccara
authors.forename: H
authors.initials: H
authors.lastname: Benamer
authors.forename: J M
authors.initials: JM
authors.lastname: Juliard
authors.forename: P
authors.initials: P
authors.lastname: Aubry
authors.forename: P
authors.initials: P
authors.lastname: Goy
authors.forename: D
authors.initials: D
authors.lastname: Himbert
authors.forename: G J
authors.initials: GJ
authors.lastname: Karrillon
authors.forename: P G
authors.initials: PG
authors.lastname: Steg
mesh_terms: D000328:Adult; D000368:Aged; D015906:Angioplasty, Balloon, Coronary; D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D003327:Coronary Disease / Q000628:therapy*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006493:Heparin / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007902:Length of Stay; D008297:Male; D008875:Middle Aged; D011292:Premedication; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000925:Anticoagulants; D006493:Heparin